1. Home
  2. BLTE vs ST Comparison

BLTE vs ST Comparison

Compare BLTE & ST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Belite Bio Inc

BLTE

Belite Bio Inc

N/A

Current Price

$163.68

Market Cap

6.0B

Sector

Health Care

ML Signal

N/A

Logo Sensata Technologies Holding plc

ST

Sensata Technologies Holding plc

N/A

Current Price

$42.15

Market Cap

6.3B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
BLTE
ST
Founded
2018
1916
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
6.3B
IPO Year
2021
2009

Fundamental Metrics

Financial Performance
Metric
BLTE
ST
Price
$163.68
$42.15
Analyst Decision
Strong Buy
Buy
Analyst Count
9
11
Target Price
★ $228.89
$53.30
AVG Volume (30 Days)
168.4K
★ 1.2M
Earning Date
11-09-2026
10-27-2026
Dividend Yield
N/A
★ 1.16%
EPS Growth
★ N/A
N/A
EPS
N/A
★ 1.29
Revenue
N/A
★ $3,704,500,000.00
Revenue This Year
N/A
$4.49
Revenue Next Year
N/A
$4.31
P/E Ratio
★ N/A
$32.51
Revenue Growth
★ N/A
N/A
52 Week Low
$72.65
$28.16
52 Week High
$200.00
$53.89

Technical Indicators

Market Signals
Indicator
BLTE
ST
Relative Strength Index (RSI) 51.47 42.98
Support Level $167.28 $40.44
Resistance Level $172.02 $43.16
Average True Range (ATR) 5.28 0.86
MACD -0.86 0.07
Stochastic Oscillator 39.80 25.69

Price Performance

Historical Comparison
BLTE
ST

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

About ST Sensata Technologies Holding plc

Sensata Technologies is a global supplier of sensors and electrical protection for transportation and industrial applications. Sensata sells a bevy of pressure, temperature, force, and position sensors into the automotive, heavy vehicle, industrial, heating, ventilation, and cooling, and aerospace markets. It also sells electrical protection products, like contactors and relays. The majority of the firm's revenue comes from the automotive market, where it focuses on bumper-in applications.

Share on Social Networks: